Opinion|Videos|March 28, 2025
Obe-Cel for B-ALL: Insights Regarding Persistence, Toxicity, and Remission
Experts discuss the steps taken to ensure optimal T-cell persistence with chimeric antigen receptor (CAR) T-cell therapy, exploring the underlying mechanisms of toxicity and T-cell exhaustion and the advantages of fast off-rate kinetics, defining durable remission post CAR T-cell therapy, and sharing their views on the benefits and risks of approved CAR T-cell therapies for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
Advertisement
Video content above is prompted by the following:
- What steps do you take to ensure the greatest T-cell persistence rate with CAR T-cell therapy?
- With respect to toxicity and T-cell exhaustion, please explore the underlying mechanisms and advantages of fast off-rate kinetics.
- In your opinion, what constitutes durable remission post CAR T- cell therapy?
- Please share your views on the benefits and risks of approved and available CAR T-cell therapies for the adult patient population with relapsed or refractory B-ALL.
Advertisement
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5